|Bid||5,050.00 x 6100|
|Ask||5,290.00 x 13000|
|Day's Range||5,120.00 - 5,172.00|
|52 Week Range||3,996.00 - 5,520.00|
|PE Ratio (TTM)||19.30|
|Dividend & Yield||2.80 (4.19%)|
|1y Target Est||N/A|
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.